Professional
Added to YB: 2024-06-18
Pitch date: 2024-06-17
CATX [bullish]
Perspective Therapeutics, Inc.
-75%
current return
Author Info
Trickle Research is an independent microcap research firm. Visit the website.
Company Info
Perspective Therapeutics, Inc., together with its subsidiaries, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States.
Market Cap
$177.0M
Pitch Price
$10.68
Price Target
22.50 (+743%)
Dividend
N/A
EV/EBITDA
0.43
P/E
-1.98
EV/Sales
-21.01
Sector
Biotechnology
Category
growth
Perspective Therapeutics - price target and allocation increase
CATX: Raised price target to $22.50 & allocation to 5 on less dilution than expected, $240-250M cash raised YTD, promising 61.5% ORR in Ph2 NET trial despite recent weakness. Risks: More dilution, failed trials. 1:10 reverse split. Model: ~$500M revs, ~50% margins, $22.50 PT on ~20x P/E by 2032.
Read full article (7 min)